BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Borra LC, Roodnat JI, Kal JA, Mathot RA, Weimar W, van Gelder T. High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation. Nephrol Dial Transplant. 2010;25:2757-2763. [PMID: 20190242 DOI: 10.1093/ndt/gfq096] [Cited by in Crossref: 159] [Cited by in F6Publishing: 147] [Article Influence: 13.3] [Reference Citation Analysis]
Number Citing Articles
1 Yabuki H, Matsuda Y, Watanabe T, Eba S, Hoshi F, Hirama T, Oishi H, Sado T, Noda M, Sakurada A, Kikuchi M, Yamaguchi H, Mano N, Okada Y. Plasma mycophenolic acid concentration and the clinical outcome after lung transplantation. Clin Transplant 2020;34. [DOI: 10.1111/ctr.14088] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Decrocq-Rudler MA, Chan Kwong AHP, Meunier L, Fraisse J, Ursic-Bedoya J, Khier S. Can We Predict Individual Concentrations of Tacrolimus After Liver Transplantation? Application and Tweaking of a Published Population Pharmacokinetic Model in Clinical Practice. Ther Drug Monit 2021;43:490-8. [PMID: 33560099 DOI: 10.1097/FTD.0000000000000867] [Reference Citation Analysis]
3 Cooper M, Dunne I, Kuten S, Curtis A, Graviss EA, Nguyen DT, Hobeika M, Gaber AO. Impact of Protease Inhibitor-Based Antiretroviral Therapy on Tacrolimus Intrapatient Variability in HIV-Positive Kidney Transplant Recipients. Transplant Proc 2021;53:984-8. [PMID: 33246588 DOI: 10.1016/j.transproceed.2020.10.003] [Reference Citation Analysis]
4 Scheel J, Reber S, Stoessel L, Waldmann E, Jank S, Eckardt KU, Grundmann F, Vitinius F, de Zwaan M, Bertram A, Erim Y. Patient-reported non-adherence and immunosuppressant trough levels are associated with rejection after renal transplantation. BMC Nephrol 2017;18:107. [PMID: 28356080 DOI: 10.1186/s12882-017-0517-6] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 6.6] [Reference Citation Analysis]
5 Ma MK, Kwan LP, Mok MM, Yap DY, Tang CS, Chan TM. Significant reduction of Tacrolimus trough level after conversion from twice daily Prograf to once daily Advagraf in Chinese renal transplant recipients with or without concomitant diltiazem treatment. Renal Failure 2013;35:942-5. [DOI: 10.3109/0886022x.2013.808134] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
6 Rozen-Zvi B, Schneider S, Lichtenberg S, Green H, Cohen O, Gafter U, Chagnac A, Mor E, Rahamimov R. Association of the combination of time-weighted variability of tacrolimus blood level and exposure to low drug levels with graft survival after kidney transplantation. Nephrol Dial Transplant 2017;32:393-9. [PMID: 28025383 DOI: 10.1093/ndt/gfw394] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
7 Rayar M, Tron C, Jézéquel C, Beaurepaire JM, Petitcollin A, Houssel-debry P, Camus C, Verdier MC, Dehlawi A, Lakéhal M, Desfourneaux V, Meunier B, Sulpice L, Bellissant E, Boudjema K, Lemaitre F. High Intrapatient Variability of Tacrolimus Exposure in the Early Period After Liver Transplantation Is Associated With Poorer Outcomes. Transplantation 2018;102:e108-14. [DOI: 10.1097/tp.0000000000002052] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
8 Süsal C, Aykut G, Morath C, Fichtner A, Unterrainer C, Scherer S, Tran TH, Mehrabi A, Zeier M, Tönshoff B. Relevance of donor-specific antibody monitoring after kidney transplantation: Findings from the Collaborative Transplant Study and the Heidelberg Transplant Center. HLA 2019;94 Suppl 2:11-5. [PMID: 31403240 DOI: 10.1111/tan.13665] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
9 Park Y, Lee H, Eum SH, Kim HD, Ko EJ, Yang CW, Chung BH. Intrapatient Variability in Tacrolimus Trough Levels Over 2 Years Affects Long-Term Allograft Outcomes of Kidney Transplantation. Front Immunol 2021;12:746013. [PMID: 34659243 DOI: 10.3389/fimmu.2021.746013] [Reference Citation Analysis]
10 Bunthof KLW, Al-Hassany L, Nakshbandi G, Hesselink DA, van Schaik RHN, Ten Dam MAGJ, Baas MC, Hilbrands LB, van Gelder T. A randomized crossover study comparing different tacrolimus formulations to reduce intrapatient variability in tacrolimus exposure in kidney transplant recipients. Clin Transl Sci 2021. [PMID: 34905302 DOI: 10.1111/cts.13206] [Reference Citation Analysis]
11 Meçule A, Tinti F, Bachetoni A, Poli L, D'alessandro M, Alessandri C, Umbro I, Nofroni I, Berloco P, Mitterhofer A. Interleukin-2 Profiles Shortly After Tacrolimus Conversion From a Twice-Daily to Once-Daily Regimen. Transplantation Proceedings 2011;43:1017-9. [DOI: 10.1016/j.transproceed.2011.02.047] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
12 Cherukuri A, Salama AD, Mehta R, Mohib K, Zheng L, Magee C, Harber M, Stauss H, Baker RJ, Tevar A, Landsittel D, Lakkis FG, Hariharan S, Rothstein DM. Transitional B cell cytokines predict renal allograft outcomes. Sci Transl Med 2021;13:eabe4929. [PMID: 33627487 DOI: 10.1126/scitranslmed.abe4929] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
13 Min S, Ha J, Kim YS, Ahn SH, Park T, Park DD, Kim SM, Min S, Hong H, Ahn C, Kim SJ. Therapeutic equivalence and pharmacokinetics of generic tacrolimus formulation in de novo kidney transplant patients. Nephrology Dialysis Transplantation 2013;28:3110-9. [DOI: 10.1093/ndt/gft300] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
14 McGillicuddy JW, Chandler JL, Sox LR, Taber DJ. Exploratory Analysis of the Impact of an mHealth Medication Adherence Intervention on Tacrolimus Trough Concentration Variability: Post Hoc Results of a Randomized Controlled Trial. Ann Pharmacother 2020;54:1185-93. [PMID: 32506922 DOI: 10.1177/1060028020931806] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
15 Koop DR, Bleyle LA, Munar M, Cherala G, Al-Uzri A. Analysis of tacrolimus and creatinine from a single dried blood spot using liquid chromatography tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2013;926:54-61. [PMID: 23548676 DOI: 10.1016/j.jchromb.2013.02.035] [Cited by in Crossref: 55] [Cited by in F6Publishing: 48] [Article Influence: 6.1] [Reference Citation Analysis]
16 Stifft F, Stolk LM, Undre N, van Hooff JP, Christiaans MH. Lower variability in 24-hour exposure during once-daily compared to twice-daily tacrolimus formulation in kidney transplantation. Transplantation 2014;97:775-80. [PMID: 24686426 DOI: 10.1097/01.TP.0000437561.31212.0e] [Cited by in Crossref: 33] [Cited by in F6Publishing: 19] [Article Influence: 4.1] [Reference Citation Analysis]
17 Jouve T, Rostaing L, Malvezzi P. New formulations of tacrolimus and prevention of acute and chronic rejections in adult kidney-transplant recipients. Expert Opinion on Drug Safety 2017;16:845-55. [DOI: 10.1080/14740338.2017.1328051] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
18 Loucks J, Yost S, Kaplan B. An introduction to basic pharmacokinetics. Transplantation 2015;99:903-7. [PMID: 25886919 DOI: 10.1097/TP.0000000000000754] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
19 Pinon M, De Nicolò A, Pizzol A, Antonucci M, D'Avolio A, Serpe L, Dell'Olio D, Catalano S, Tandoi F, Romagnoli R, Canaparo R, Calvo PL. Early impact of donor CYP3A5 genotype and Graft-to-Recipient Weight Ratio on tacrolimus pharmacokinetics in pediatric liver transplant patients. Sci Rep 2021;11:443. [PMID: 33432012 DOI: 10.1038/s41598-020-79574-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
20 Kuypers DRJ. Intrapatient Variability of Tacrolimus Exposure in Solid Organ Transplantation: A Novel Marker for Clinical Outcome. Clin Pharmacol Ther 2020;107:347-58. [PMID: 31449663 DOI: 10.1002/cpt.1618] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 10.3] [Reference Citation Analysis]
21 Veenhof H, van Boven JFM, van der Voort A, Berger SP, Bakker SJL, Touw DJ. Effects, costs and implementation of monitoring kidney transplant patients' tacrolimus levels with dried blood spot sampling: A randomized controlled hybrid implementation trial. Br J Clin Pharmacol 2020;86:1357-66. [PMID: 32077134 DOI: 10.1111/bcp.14249] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
22 Shen CL, Yang AH, Lien TJ, Tarng DC, Yang CY. Tacrolimus Blood Level Fluctuation Predisposes to Coexisting BK Virus Nephropathy and Acute Allograft Rejection. Sci Rep 2017;7:1986. [PMID: 28512328 DOI: 10.1038/s41598-017-02140-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
23 Song T, Yin S, Jiang Y, Huang Z, Liu J, Wang Z, Li L, Zeng J, Fan Y, Wang X, Li X, Lin T. Increasing Time in Therapeutic Range of Tacrolimus in the First Year Predicts Better Outcomes in Living-Donor Kidney Transplantation. Front Immunol 2019;10:2912. [PMID: 31921171 DOI: 10.3389/fimmu.2019.02912] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
24 Ensor CR, Iasella CJ, Harrigan KM, Morrell MR, Moore CA, Shigemura N, Zeevi A, McDyer JF, Venkataramanan R. Increasing tacrolimus time-in-therapeutic range is associated with superior one-year outcomes in lung transplant recipients. Am J Transplant 2018;18:1527-33. [PMID: 29513387 DOI: 10.1111/ajt.14723] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
25 Prytula AA, Bouts AH, Mathot RAA, van Gelder T, Croes LK, Hop W, Cransberg K. Intra-patient variability in tacrolimus trough concentrations and renal function decline in pediatric renal transplant recipients: Intra-patient tacrolimus levels variability. Pediatric Transplantation 2012;16:613-8. [DOI: 10.1111/j.1399-3046.2012.01727.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 3.3] [Reference Citation Analysis]
26 Seibert SR, Schladt DP, Wu B, Guan W, Dorr C, Remmel RP, Matas AJ, Mannon RB, Israni AK, Oetting WS, Jacobson PA. Tacrolimus trough and dose intra-patient variability and CYP3A5 genotype: Effects on acute rejection and graft failure in European American and African American kidney transplant recipients. Clin Transplant 2018;32:e13424. [PMID: 30318646 DOI: 10.1111/ctr.13424] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
27 Pashaee N, Bouamar R, Hesselink DA, Roodnat JI, van Schaik RH, Weimar W, van Gelder T. CYP3A5 genotype is not related to the intrapatient variability of tacrolimus clearance. Ther Drug Monit 2011;33:369-71. [PMID: 21566507 DOI: 10.1097/FTD.0b013e31821a7aa3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 5] [Article Influence: 1.9] [Reference Citation Analysis]
28 Larpparisuth N, Skulratanasak P, Vongwiwatana A, Premasathian N. Effect on Dosage Change and Intrapatient Variability After Conversion From Twice-Daily to Once-Daily Tacrolimus Among Thai Kidney Transplant Patients With and Without CYP3A4/5 Inhibitors. Transplant Proc 2019;51:2620-3. [PMID: 31474450 DOI: 10.1016/j.transproceed.2019.02.065] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
29 Cheung CY, Chan KM, Wong YT, Chak WL, Bekers O, van Hooff JP. Impact of CYP3A5 Genetic Polymorphism on Intrapatient Variability of Tacrolimus Exposure in Chinese Kidney Transplant Recipients. Transplantation Proceedings 2019;51:1754-7. [DOI: 10.1016/j.transproceed.2019.04.019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
30 Jouve T, Noble J, Rostaing L, Malvezzi P. An update on the safety of tacrolimus in kidney transplant recipients, with a focus on tacrolimus minimization. Expert Opinion on Drug Safety 2019;18:285-94. [DOI: 10.1080/14740338.2019.1599858] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
31 van der Veer MAA, Nangrahary N, Hesselink DA, Erler NS, Metselaar HJ, van Gelder T, Darwish Murad S. High Intrapatient Variability in Tacrolimus Exposure Is Not Associated With Immune-mediated Graft Injury After Liver Transplantation. Transplantation 2019;103:2329-37. [PMID: 30801539 DOI: 10.1097/TP.0000000000002680] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 3.5] [Reference Citation Analysis]
32 Rummo OO, Carmellini M, Rostaing L, Oberbauer R, Christiaans MHL, Mousson C, Langer RM, Citterio F, Charpentier B, Brown M, Kazeem G, Lehner F; the ADHERE study investigators. ADHERE: randomized controlled trial comparing renal function in de novo kidney transplant recipients receiving prolonged-release tacrolimus plus mycophenolate mofetil or sirolimus. Transpl Int 2017;30:83-95. [DOI: 10.1111/tri.12878] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
33 Chavant A, Fonrose X, Gautier-Veyret E, Hilleret MN, Roustit M, Stanke-Labesque F. Variability of Tacrolimus Trough Concentration in Liver Transplant Patients: Which Role of Inflammation? Pharmaceutics 2021;13:1960. [PMID: 34834375 DOI: 10.3390/pharmaceutics13111960] [Reference Citation Analysis]
34 Shuker N, Cadogan M, van Gelder T, Roodnat JI, Kho MM, Weimar W, Hesselink DA. Conversion from twice-daily to once-daily tacrolimus does not reduce intrapatient variability in tacrolimus exposure. Ther Drug Monit. 2015;37:262-269. [PMID: 25265255 DOI: 10.1097/ftd.0000000000000136] [Cited by in Crossref: 19] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
35 Kuypers DRJ. From Nonadherence to Adherence. Transplantation 2020;104:1330-40. [PMID: 31929426 DOI: 10.1097/TP.0000000000003112] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
36 Zheng Y, Masand A, Wagner M, Kapur S, Dadhania D, Lubetzky M, Lee JR. Identification of Antibiotic Administration as a Potentially Novel Factor Associated With Tacrolimus Trough Variability in Kidney Transplant Recipients: A Preliminary Study. Transplant Direct. 2019;5:e485. [PMID: 31579813 DOI: 10.1097/txd.0000000000000930] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
37 Yin S. Post-transplant donor-specific antibody and outcomes with T cell-mediated rejection and nonadherence. Kidney Int 2020;98:515-6. [PMID: 32709296 DOI: 10.1016/j.kint.2020.01.047] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
38 Hwang S, Song GW, Jung DH, Park GC, Ahn CS, Moon DB, Ha TY, Kim KH, Lee SG. Intra-individual variability of mycophenolic acid concentration according to renal function in liver transplant recipients receiving mycophenolate monotherapy. Ann Hepatobiliary Pancreat Surg 2017;21:11-6. [PMID: 28317040 DOI: 10.14701/ahbps.2017.21.1.11] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
39 Albano L, Banas B, Klempnauer JL, Glyda M, Viklicky O, Kamar N. OSAKA trial: a randomized, controlled trial comparing tacrolimus QD and BD in kidney transplantation. Transplantation. 2013;96:897-903. [PMID: 23982340 DOI: 10.1097/tp.0b013e3182a203bd] [Cited by in Crossref: 52] [Cited by in F6Publishing: 18] [Article Influence: 6.5] [Reference Citation Analysis]
40 Kohut TJ, Barandiaran JF, Keating BJ. Genomics and Liver Transplantation: Genomic Biomarkers for the Diagnosis of Acute Cellular Rejection. Liver Transpl 2020;26:1337-50. [DOI: 10.1002/lt.25812] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
41 Shuker N, van Gelder T, Hesselink DA. Intra-patient variability in tacrolimus exposure: causes, consequences for clinical management. Transplant Rev (Orlando). 2015;29:78-84. [PMID: 25687818 DOI: 10.1016/j.trre.2015.01.002] [Cited by in Crossref: 104] [Cited by in F6Publishing: 92] [Article Influence: 14.9] [Reference Citation Analysis]
42 Schumacher L, Leino AD, Park JM. Tacrolimus intrapatient variability in solid organ transplantation: A multiorgan perspective. Pharmacotherapy 2021;41:103-18. [PMID: 33131078 DOI: 10.1002/phar.2480] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
43 Slatinska J, Rohal T, Wohlfahrtova M, Viklicky O. Long-term Follow-up of Stable Kidney Transplant Recipients After Conversion From Tacrolimus Twice Daily Immediate Release to Tacrolimus Once-daily Prolonged Release: A Large Single-Center Experience. Transplantation Proceedings 2013;45:1491-6. [DOI: 10.1016/j.transproceed.2012.11.017] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
44 Staatz CE, Tett SE. Clinical Pharmacokinetics of Once-Daily Tacrolimus in Solid-Organ Transplant Patients. Clin Pharmacokinet 2015;54:993-1025. [DOI: 10.1007/s40262-015-0282-2] [Cited by in Crossref: 54] [Cited by in F6Publishing: 42] [Article Influence: 7.7] [Reference Citation Analysis]
45 Gallagher HM, Sarwar G, Tse T, Sladden TM, Hii E, Yerkovich ST, Hopkins PM, Chambers DC. Erratic tacrolimus exposure, assessed using the standard deviation of trough blood levels, predicts chronic lung allograft dysfunction and survival. The Journal of Heart and Lung Transplantation 2015;34:1442-8. [DOI: 10.1016/j.healun.2015.05.028] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
46 Jones-Hughes T, Snowsill T, Haasova M, Coelho H, Crathorne L, Cooper C, Mujica-Mota R, Peters J, Varley-Campbell J, Huxley N, Moore J, Allwood M, Lowe J, Hyde C, Hoyle M, Bond M, Anderson R. Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model. Health Technol Assess 2016;20:1-594. [PMID: 27578428 DOI: 10.3310/hta20620] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
47 Fernandez HE, Amaral S, Shaw PA, Doyle AM, Bloom RD, Palmer JA, Baluarte HJ, Furth SL. The effect of transfer to adult transplant care on kidney function and immunosuppressant drug level variability in pediatric kidney transplant recipients. Pediatr Transplant 2019;23. [DOI: 10.1111/petr.13527] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
48 Ong SC, Gaston RS. Thirty Years of Tacrolimus in Clinical Practice. Transplantation 2021;105:484-95. [PMID: 32541562 DOI: 10.1097/TP.0000000000003350] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
49 Halleck F, Friedersdorff F, Fuller T, Matz M, Huber L, Dürr M, Schütz M, Budde K. New Perspectives of Immunosuppression. Transplantation Proceedings 2013;45:1224-31. [DOI: 10.1016/j.transproceed.2013.02.033] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
50 Egeland EJ, Robertsen I, Hermann M, Midtvedt K, Størset E, Gustavsen MT, Reisæter AV, Klaasen R, Bergan S, Holdaas H, Hartmann A, Åsberg A. High Tacrolimus Clearance Is a Risk Factor for Acute Rejection in the Early Phase After Renal Transplantation. Transplantation 2017;101:e273-9. [DOI: 10.1097/tp.0000000000001796] [Cited by in Crossref: 28] [Cited by in F6Publishing: 12] [Article Influence: 5.6] [Reference Citation Analysis]
51 van Bezooijen JS, Schreurs MWJ, Koch BCP, Velthuis HT, van Doorn MBA, Prens EP, van Gelder T. Intrapatient Variability in the Pharmacokinetics of Etanercept Maintenance Treatment. Ther Drug Monit 2017;39:333-8. [PMID: 28691952 DOI: 10.1097/FTD.0000000000000384] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
52 Ghareeb M, Akhlaghi F. Development and validation of a sensitive and selective LC–MS/MS method for determination of tacrolimus in oral fluids. Journal of Chromatography B 2016;1038:136-41. [DOI: 10.1016/j.jchromb.2016.10.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
53 Meçule A, Tinti F, Poli L, Bachetoni A, Umbro I, Nofroni I, Lai Q, Pretagostini R, Berloco PB, Mitterhofer AP. Tacrolimus trough levels and level-to-dose ratio in stable renal transplant patients converted to a once-daily regimen. Transplant Proc 2011;43:1024-7. [PMID: 21620042 DOI: 10.1016/j.transproceed.2011.02.049] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
54 Herblum J, Dacouris N, Huang M, Zaltzman J, Prasad GVR, Nash M, Chen L. Retrospective Analysis of Tacrolimus Intrapatient Variability as a Measure of Medication Adherence. Can J Kidney Health Dis 2021;8:20543581211021742. [PMID: 34188946 DOI: 10.1177/20543581211021742] [Reference Citation Analysis]
55 Maciel NB, Schwambach KH, Blatt CR. LIVER TRANSPLANTATION: TACROLIMUS BLOOD LEVELS VARIATION AND SURVIVAL, REJECTION AND DEATH OUTCOMES. Arq Gastroenterol 2021;58:370-6. [PMID: 34705973 DOI: 10.1590/S0004-2803.202100000-62] [Reference Citation Analysis]
56 Nnani DU, Campbell A, Ajaimy M, Saeed O, Patel SR, Ahmed S, Graham JA, Jorde UP. Effect of glecaprevir/pibrentasvir on weight-adjusted tacrolimus trough/dose ratios in heart and kidney transplant recipients. Transpl Infect Dis 2021;23:e13716. [PMID: 34407270 DOI: 10.1111/tid.13716] [Reference Citation Analysis]
57 Kaya Aksoy G, Comak E, Koyun M, Akbaş H, Akkaya B, Aydınlı B, Uçar F, Akman S. Tacrolimus Variability: A Cause of Donor-Specific Anti-HLA Antibody Formation in Children. Eur J Drug Metab Pharmacokinet 2019;44:539-48. [DOI: 10.1007/s13318-019-00544-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
58 van Gelder T, Meziyerh S, Swen JJ, de Vries APJ, Moes DJAR. The Clinical Impact of the C0/D Ratio and the CYP3A5 Genotype on Outcome in Tacrolimus Treated Kidney Transplant Recipients. Front Pharmacol 2020;11:1142. [PMID: 32848756 DOI: 10.3389/fphar.2020.01142] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
59 Spierings N, Holt DW, MacPhee IA. CYP3A5 genotype had no impact on intrapatient variability of tacrolimus clearance in renal transplant recipients. Ther Drug Monit. 2013;35:328-331. [PMID: 23666583 DOI: 10.1097/ftd.0b013e318289644d] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
60 Johnston A. Equivalence and interchangeability of narrow therapeutic index drugs in organ transplantation. Eur J Hosp Pharm 2013;20:302-7. [PMID: 24089632 DOI: 10.1136/ejhpharm-2012-000258] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
61 Beck DK, Tielen M, Rechards M, Timman R, Boonstra C, Versteegh J, van de Wetering J, Zietse R, van Gelder T, Weimar W, van Saase J, van Busschbach J, Massey EK. Comparison of a home-based (multi) systemic intervention to promoting Medication AdheRence and Self-management among kidney transplant recipients with care-as-usual: the MARS randomized controlled trial protocol. BMC Nephrol 2020;21:374. [PMID: 32859157 DOI: 10.1186/s12882-020-02008-z] [Reference Citation Analysis]
62 Cowlrick I. Children deserve the same level of post-transplant care as adults: Role of extemporaneous formulations and conversion to licensed formulations. Pediatr Transplantation 2018;22:e13182. [DOI: 10.1111/petr.13182] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
63 Tielen M, van Exel J, Laging M, Beck DK, Khemai R, van Gelder T, Betjes MG, Weimar W, Massey EK. Attitudes to medication after kidney transplantation and their association with medication adherence and graft survival: A 2-year follow-up study. J Transplant. 2014;2014:675301. [PMID: 24868449 DOI: 10.1155/2014/675301] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 4.4] [Reference Citation Analysis]
64 Jung HY, Cho SY, Choi JY, Cho JH, Park SH, Kim YL, Kim HK, Huh S, Won DI, Kim CD. Comparison of Transplant Outcomes for Low-level and Standard-level Tacrolimus at Different Time Points after Kidney Transplantation. J Korean Med Sci 2019;34:e103. [PMID: 30940998 DOI: 10.3346/jkms.2019.34.e103] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
65 Schwartz JJ, Lee E, Butler AP, Facklam DP, Franks B, Spalding JR, Vassilakis ME, Thal GD, Irish WD. The Association of Tacrolimus Formulation Switching with Trough Concentration Variability: A Retrospective Cohort Study of Tacrolimus Use Post-Kidney Transplantation Based on National Drug Code (NDC) Numbers. Adv Ther 2019;36:1358-69. [PMID: 31004326 DOI: 10.1007/s12325-019-00950-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
66 Banas B, Krämer BK, Krüger B, Kamar N, Undre N. Long-Term Kidney Transplant Outcomes: Role of Prolonged-Release Tacrolimus. Transplant Proc 2020;52:102-10. [PMID: 31901329 DOI: 10.1016/j.transproceed.2019.11.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
67 Sukkha S, Suansanae T, Iamrahong P, Wiwattanathum P. Trough Level and Tacrolimus Variability of Early Converted Once-Daily Tacrolimus: 1-Year Follow-up Study. Transplant Proc 2020;52:775-9. [PMID: 32143870 DOI: 10.1016/j.transproceed.2019.12.039] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
68 Rahamimov R, Tifti-Orbach H, Zingerman B, Green H, Schneider S, Chagnac A, Mor E, Fox BD, Rozen-Zvi B. Reduction of exposure to tacrolimus trough level variability is associated with better graft survival after kidney transplantation. Eur J Clin Pharmacol 2019;75:951-8. [PMID: 30762079 DOI: 10.1007/s00228-019-02643-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
69 Stefanović NZ, Veličković-Radovanović RM, Danković KS, Mitić BP, Paunović GJ, Cvetković MB, Cvetković TP. Combined Effect of Inter- and Intrapatient Variability in Tacrolimus Exposure on Graft Impairment Within a 3-Year Period Following Kidney Transplantation: A Single-Center Experience. Eur J Drug Metab Pharmacokinet 2020;45:749-60. [PMID: 32886348 DOI: 10.1007/s13318-020-00644-2] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
70 Sablik KA, Clahsen-van Groningen MC, Hesselink DA, van Gelder T, Betjes MGH. Tacrolimus intra-patient variability is not associated with chronic active antibody mediated rejection. PLoS One 2018;13:e0196552. [PMID: 29746495 DOI: 10.1371/journal.pone.0196552] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 4.8] [Reference Citation Analysis]
71 Gonzales HM, McGillicuddy JW, Rohan V, Chandler JL, Nadig SN, Dubay DA, Taber DJ. A comprehensive review of the impact of tacrolimus intrapatient variability on clinical outcomes in kidney transplantation. Am J Transplant 2020;20:1969-83. [PMID: 32406604 DOI: 10.1111/ajt.16002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
72 Kim J, Wilson S, Undre NA, Shi F, Kristy RM, Schwartz JJ. A Novel, Dose-Adjusted Tacrolimus Trough-Concentration Model for Predicting and Estimating Variance After Kidney Transplantation. Drugs R D 2019;19:201-12. [PMID: 31073875 DOI: 10.1007/s40268-019-0271-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
73 Vanhove T, Vermeulen T, Annaert P, Lerut E, Kuypers DRJ. High Intrapatient Variability of Tacrolimus Concentrations Predicts Accelerated Progression of Chronic Histologic Lesions in Renal Recipients. Am J Transplant. 2016;16:2954-2963. [PMID: 27013142 DOI: 10.1111/ajt.13803] [Cited by in Crossref: 70] [Cited by in F6Publishing: 63] [Article Influence: 11.7] [Reference Citation Analysis]
74 Harrison JJ, Schiff JR, Coursol CJ, Daley CJ, Dipchand AI, Heywood NM, Keough-Ryan TM, Keown PA, Levy GA, Lien DC, Wichart JR, Cantarovich M. Generic immunosuppression in solid organ transplantation: a Canadian perspective. Transplantation 2012;93:657-65. [PMID: 22267158 DOI: 10.1097/TP.0b013e3182445e9d] [Cited by in Crossref: 43] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
75 Robertsen I, Åsberg A, Ingerø AO, Vethe NT, Bremer S, Bergan S, Midtvedt K. Use of Generic Tacrolimus in Elderly Renal Transplant Recipients: Precaution Is Needed. Transplantation 2015;99:528-32. [DOI: 10.1097/tp.0000000000000384] [Cited by in Crossref: 32] [Cited by in F6Publishing: 7] [Article Influence: 4.6] [Reference Citation Analysis]
76 Arias M, Serón D, Herrero I, Rush DN, Wiebe C, Nickerson PW, Ussetti P, Rodrigo E, de Cos M. Subclinical Antibody-Mediated Rejection. Transplantation 2017;101:S1-S18. [DOI: 10.1097/tp.0000000000001735] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
77 Brunet M, van Gelder T, Åsberg A, Haufroid V, Hesselink DA, Langman L, Lemaitre F, Marquet P, Seger C, Shipkova M, Vinks A, Wallemacq P, Wieland E, Woillard JB, Barten MJ, Budde K, Colom H, Dieterlen M, Elens L, Johnson-davis KL, Kunicki PK, Macphee I, Masuda S, Mathew BS, Millán O, Mizuno T, Moes DAR, Monchaud C, Noceti O, Pawinski T, Picard N, van Schaik R, Sommerer C, Vethe NT, de Winter B, Christians U, Bergan S. Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. Therapeutic Drug Monitoring 2019;41:261-307. [DOI: 10.1097/ftd.0000000000000640] [Cited by in Crossref: 131] [Cited by in F6Publishing: 46] [Article Influence: 43.7] [Reference Citation Analysis]
78 Whalen HR, Glen JA, Harkins V, Stevens KK, Jardine AG, Geddes CC, Clancy MJ. High Intrapatient Tacrolimus Variability Is Associated With Worse Outcomes in Renal Transplantation Using a Low-Dose Tacrolimus Immunosuppressive Regime. Transplantation 2017;101:430-6. [PMID: 26950724 DOI: 10.1097/TP.0000000000001129] [Cited by in Crossref: 44] [Cited by in F6Publishing: 17] [Article Influence: 8.8] [Reference Citation Analysis]
79 Dorr CR, Oetting WS, Jacobson PA, Israni AK. Genetics of acute rejection after kidney transplantation. Transpl Int 2018;31:263-77. [PMID: 29030886 DOI: 10.1111/tri.13084] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
80 Krämer B, Albano L, Banas B, Charpentier B, Bäckman L, Tedesco-silva H, Lehner F, Mondragón-ramírez G, Glyda M, Cassuto-viguier E, Viklický O, Mourad G, Rigotti P, Schleibner S, Kamar N. Efficacy of Prolonged- and Immediate-release Tacrolimus in Kidney Transplantation: A Pooled Analysis of Two Large, Randomized, Controlled Trials. Transplantation Proceedings 2017;49:2040-9. [DOI: 10.1016/j.transproceed.2017.07.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
81 Del Bello A, Congy-Jolivet N, Danjoux M, Muscari F, Lavayssière L, Esposito L, Hebral AL, Bellière J, Kamar N. High tacrolimus intra-patient variability is associated with graft rejection, and de novo donor-specific antibodies occurrence after liver transplantation. World J Gastroenterol 2018; 24(16): 1795-1802 [PMID: 29713132 DOI: 10.3748/wjg.v24.i16.1795] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 27] [Article Influence: 9.3] [Reference Citation Analysis]
82 van Boekel GA, Aarnoutse RE, van der Heijden JJ, Hoogtanders KE, Hilbrands LB. Effect of Mild Diarrhea on Tacrolimus Exposure. Transplantation 2012;94:763-7. [DOI: 10.1097/tp.0b013e3182629e13] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
83 Jouve T, Fonrose X, Noble J, Janbon B, Fiard G, Malvezzi P, Stanke-Labesque F, Rostaing L. The TOMATO Study (Tacrolimus Metabolization in Kidney Transplantation): Impact of the Concentration-Dose Ratio on Death-censored Graft Survival. Transplantation 2020;104:1263-71. [PMID: 31415035 DOI: 10.1097/TP.0000000000002920] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 8.5] [Reference Citation Analysis]
84 Golubović B, Vučićević K, Radivojević D, Kovačević SV, Prostran M, Miljković B. Total plasma protein effect on tacrolimus elimination in kidney transplant patients – Population pharmacokinetic approach. European Journal of Pharmaceutical Sciences 2014;52:34-40. [DOI: 10.1016/j.ejps.2013.10.008] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
85 Ro H, Min SI, Yang J, Moon KC, Kim YS, Kim SJ, Ahn C, Ha J. Impact of tacrolimus intraindividual variability and CYP3A5 genetic polymorphism on acute rejection in kidney transplantation. Ther Drug Monit. 2012;34:680-685. [PMID: 23149441 DOI: 10.1097/ftd.0b013e3182731809] [Cited by in Crossref: 44] [Cited by in F6Publishing: 16] [Article Influence: 4.9] [Reference Citation Analysis]
86 Alghanem SS, Soliman MM, Alibrahim AA, Gheith O, Kenawy AS, Awad A. Monitoring Tacrolimus Trough Concentrations During the First Year After Kidney Transplantation: A National Retrospective Cohort Study. Front Pharmacol 2020;11:566638. [PMID: 33658922 DOI: 10.3389/fphar.2020.566638] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
87 Guirado L, Burgos D, Cantarell C, Fernández A, Franco A, Gentil MÁ, Mazuecos A, Torregrosa JV, Huertas EG, Ruiz JC, Plumed JS, Paul J, Lauzurica R, Zárraga S, Osuna A, Jiménez C, Alonso Á, Rodríguez A, Bardají B, Hernández D. Medium-Term Renal Function in a Large Cohort of Stable Kidney Transplant Recipients Converted From Twice-Daily to Once-Daily Tacrolimus. Transplant Direct 2015;1:e24. [PMID: 27500226 DOI: 10.1097/TXD.0000000000000536] [Cited by in Crossref: 14] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
88 Cherukuri A, Mehta R, Sharma A, Sood P, Zeevi A, Tevar AD, Rothstein DM, Hariharan S. Post-transplant donor specific antibody is associated with poor kidney transplant outcomes only when combined with both T-cell-mediated rejection and non-adherence. Kidney Int 2019;96:202-13. [PMID: 31029504 DOI: 10.1016/j.kint.2019.01.033] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
89 Li Y, Yan L, Li Y, Wan Z, Bai Y, Wang X, Hu S, Wu X, Yang C, Fan J, Xu H, Wang L, Shi Y. Development and validation of routine clinical laboratory data derived marker-based nomograms for the prediction of 5-year graft survival in kidney transplant recipients. Aging (Albany NY) 2021;13:9927-47. [PMID: 33795527 DOI: 10.18632/aging.202748] [Reference Citation Analysis]
90 Thongprayoon C, Hansrivijit P, Kovvuru K, Kanduri SR, Bathini T, Pivovarova A, Smith JR, Cheungpasitporn W. Impacts of High Intra- and Inter-Individual Variability in Tacrolimus Pharmacokinetics and Fast Tacrolimus Metabolism on Outcomes of Solid Organ Transplant Recipients. J Clin Med 2020;9:E2193. [PMID: 32664531 DOI: 10.3390/jcm9072193] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
91 Prytuła A, van Gelder T. Clinical aspects of tacrolimus use in paediatric renal transplant recipients. Pediatr Nephrol 2019;34:31-43. [DOI: 10.1007/s00467-018-3892-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
92 Kwekkeboom J, van der Laan LJ, Betjes MG, Manintveld OC, Hoek RA, Cransberg K, de Bruin RW, Dor FJ, de Jonge J, Boor PP, van Gent R, van Besouw NM, Boer K, Litjens NH, Hesselink DA, Hoogduijn MJ, Massey E, Rowshani AT, van de Wetering J, de Jong H, Hendriks RW, Metselaar HJ, van Gelder T, Weimar W, IJzermans JN, Baan CC. Rotterdam: main port for organ transplantation research in the Netherlands. Transpl Immunol 2014;31:200-6. [PMID: 25240732 DOI: 10.1016/j.trim.2014.09.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
93 Knight SR. Intrapatient variability in tacrolimus exposure - a useful tool for clinical practice? Transpl Int 2016;29:1155-7. [DOI: 10.1111/tri.12806] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
94 Gustavsen MT, Midtvedt K, Lønning K, Jacobsen T, Reisaeter AV, De Geest S, Andersen MH, Hartmann A, Åsberg A. Evaluation of tools for annual capture of adherence to immunosuppressive medications after renal transplantation - a single-centre open prospective trial. Transpl Int 2019;32:614-25. [DOI: 10.1111/tri.13412] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
95 Masutani K, Tsuchimoto A, Haruyama N, Kitada H, Okabe Y, Noguchi H, Tanaka M, Tsuruya K, Kitazono T. Protocol Biopsy Findings in Living Donor Kidney Transplant Patients Treated With Once-daily or Twice-daily Tacrolimus Formulation. Transplantation Proceedings 2014;46:395-9. [DOI: 10.1016/j.transproceed.2013.10.050] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
96 Defrancq C, De Wilde N, Raes A, Van Biervliet S, Vande Velde S, Van Winckel M, De Bruyne R, Prytuła A. Intra‐patient variability in tacrolimus exposure in pediatric liver transplant recipients: Evolution, risk factors, and impact on patient outcomes. Pediatr Transplant 2019;23. [DOI: 10.1111/petr.13388] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
97 Heeney S, Szempruch KR, Lee RM, Mintz A, Serrano P, Detwiler R, Doligalski C. The Effect of Tacrolimus Trough Variability on Kidney Transplant Outcomes. Transplant Proc 2020;52:3129-33. [PMID: 32896383 DOI: 10.1016/j.transproceed.2020.07.016] [Reference Citation Analysis]
98 Niioka T, Kagaya H, Saito M, Inoue T, Numakura K, Yamamoto R, Habuchi T, Satoh S, Miura M. Impact of the CYP3A5 genotype on the distributions of dose-adjusted trough concentrations and incidence of rejection in Japanese renal transplant recipients receiving different tacrolimus formulations. Clin Exp Nephrol 2017;21:787-96. [DOI: 10.1007/s10157-016-1375-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
99 Crespo M, Zárraga S, Alonso Á, Beneyto I, Díaz Corte C, Fernandez Rodriguez AM, Franco A, Hernández D, González-roncero FM, Jiménez Martín C, Jimeno L, Lauzurica Valdemoros L, Llorente S, Mazuecos A, Osuna A, Ramos JP, Rodríguez Benot A, Ruiz San Millán JC, Sánchez Fructuoso A, Torregrosa J, Guirado L. Monitoring of Donor-specific Anti-HLA Antibodies and Management of Immunosuppression in Kidney Transplant Recipients: An Evidence-based Expert Paper. Transplantation 2020;104:S1-S12. [DOI: 10.1097/tp.0000000000003270] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
100 McGillicuddy J, Chandler J, Sox L, Mueller M, Nemeth L, Baliga P, Treiber F. "Smartphone Medication Adherence Saves Kidneys" for Kidney Transplantation Recipients: Protocol for a Randomized Controlled Trial. JMIR Res Protoc 2019;8:e13351. [PMID: 31228175 DOI: 10.2196/13351] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
101 Oetting WS, Dorr C, Remmel RP, Matas AJ, Israni AK, Jacobson PA. Concepts of Genomics in Kidney Transplantation. Curr Transplant Rep 2017;4:116-23. [PMID: 29123971 DOI: 10.1007/s40472-017-0153-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
102 Rodrigo E, Segundo DS, Fernández-Fresnedo G, López-Hoyos M, Benito A, Ruiz JC, de Cos MA, Arias M. Within-Patient Variability in Tacrolimus Blood Levels Predicts Kidney Graft Loss and Donor-Specific Antibody Development. Transplantation 2016;100:2479-85. [PMID: 26703349 DOI: 10.1097/TP.0000000000001040] [Cited by in Crossref: 113] [Cited by in F6Publishing: 46] [Article Influence: 22.6] [Reference Citation Analysis]
103 Gueta I, Markovits N, Yarden-bilavsky H, Raichlin E, Freimark D, Lavee J, Loebstein R, Peled Y. High tacrolimus trough level variability is associated with rejections after heart transplant. Am J Transplant 2018;18:2571-8. [DOI: 10.1111/ajt.15016] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
104 Abedini S, Gøransson L, Cockburn E, Kilany S, Holdaas H. Immunosuppression Adherence in Stable Kidney Transplant Patients Converted From Immediate- to Prolonged-Release Tacrolimus in Clinical Practice: A Norwegian Study. Transplant Direct 2018;4:e338. [PMID: 29464199 DOI: 10.1097/TXD.0000000000000755] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
105 Goldsmith PM, Bottomley MJ, Okechukwu O, Ross VC, Ghita R, Wandless D, Falconer SJ, Papachristos S, Nash P, Androshchuk V, Clancy M; Transplant Audit Collaborative. Impact of intrapatient variability (IPV) in tacrolimus trough levels on long-term renal transplant function: multicentre collaborative retrospective cohort study protocol. BMJ Open 2017;7:e016144. [PMID: 28756385 DOI: 10.1136/bmjopen-2017-016144] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
106 Sapir-Pichhadze R, Wang Y, Famure O, Li Y, Kim SJ. Time-dependent variability in tacrolimus trough blood levels is a risk factor for late kidney transplant failure. Kidney Int 2014;85:1404-11. [PMID: 24336032 DOI: 10.1038/ki.2013.465] [Cited by in Crossref: 123] [Cited by in F6Publishing: 111] [Article Influence: 13.7] [Reference Citation Analysis]
107 Bunnapradist S, Ciechanowski K, West-Thielke P, Mulgaonkar S, Rostaing L, Vasudev B, Budde K; MELT investigators. Conversion from twice-daily tacrolimus to once-daily extended release tacrolimus (LCPT): the phase III randomized MELT trial. Am J Transplant 2013;13:760-9. [PMID: 23279614 DOI: 10.1111/ajt.12035] [Cited by in Crossref: 55] [Cited by in F6Publishing: 44] [Article Influence: 5.5] [Reference Citation Analysis]
108 Abu Bakar K, Mohamad NA, Hodi Z, McCulloch T, Williams A, Christian M, Key T, Kim JJ. Defining a threshold for tacrolimus intra-patient variability associated with late acute cellular rejection in paediatric kidney transplant recipients. Pediatr Nephrol 2019;34:2557-62. [PMID: 31520127 DOI: 10.1007/s00467-019-04346-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
109 Saint-Marcoux F, Woillard JB, Monchaud C, Friedl J, Bocquentin F, Essig M, Marquet P. How to handle missed or delayed doses of tacrolimus in renal transplant recipients? A pharmacokinetic investigation. Pharmacol Res 2015;100:281-7. [PMID: 26316426 DOI: 10.1016/j.phrs.2015.08.020] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
110 Gold A, Tönshoff B, Döhler B, Süsal C. Association of graft survival with tacrolimus exposure and late intra-patient tacrolimus variability in pediatric and young adult renal transplant recipients-an international CTS registry analysis. Transpl Int 2020;33:1681-92. [PMID: 32881096 DOI: 10.1111/tri.13726] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
111 Ro H, Jeong JC, Kong JM, Min JW, Park SK, Lee J, Koo TY, Yang J, Kim MS, Hwang S, Ahn C. The tacrolimus metabolism affect post‐transplant outcome mediating acute rejection and delayed graft function: analysis from Korean Organ Transplantation Registry data. Transpl Int 2021;34:163-74. [DOI: 10.1111/tri.13777] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
112 Rubik J, Debray D, Kelly D, Iserin F, Webb NJA, Czubkowski P, Vondrak K, Sellier-Leclerc AL, Rivet C, Riva S, Tönshoff B, D'Antiga L, Marks SD, Reding R, Kazeem G, Undre N. Efficacy and safety of prolonged-release tacrolimus in stable pediatric allograft recipients converted from immediate-release tacrolimus - a Phase 2, open-label, single-arm, one-way crossover study. Transpl Int 2019;32:1182-93. [PMID: 31325368 DOI: 10.1111/tri.13479] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
113 Yin S, Wang X, Huang Z, Fan Y, Song T, Lin T. Tacrolimus variability score outperforms coefficient of variation in predicting clinical outcomes of living kidney transplantation. Br J Clin Pharmacol 2021. [PMID: 33899267 DOI: 10.1111/bcp.14876] [Reference Citation Analysis]
114 Zhu J, Patel T, Miller JA, Torrice CD, Aggarwal M, Sketch MR, Alexander MD, Armistead PM, Coghill JM, Grgic T, Jamieson KJ, Ptachcinski JR, Riches ML, Serody JS, Schmitz JL, Shaw JR, Shea TC, Suzuki O, Vincent BG, Wood WA, Rao KV, Wiltshire T, Weimer ET, Crona DJ. Influence of Germline Genetics on Tacrolimus Pharmacokinetics and Pharmacodynamics in Allogeneic Hematopoietic Stem Cell Transplant Patients. Int J Mol Sci 2020;21:E858. [PMID: 32013193 DOI: 10.3390/ijms21030858] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
115 Vega-Roman C, Leal-Cortes C, Portilla-de Buen E, Gomez-Navarro B, Melo Z, Franco-Acevedo A, Medina-Perez M, Jalomo-Martinez B, Martinez-Martinez P, Evangelista-Carrillo LA, Cerrillos-Gutierrez JI, Andrade-Sierra J, Nieves JJ, Gone-Vazquez I, Escobedo-Ruiz A, Jave-Suarez LF, Luquin S, Echavarria R. Impact of transplantation on neutrophil extracellular trap formation in patients with end-stage renal disease: A single-center, prospective cohort study. Medicine (Baltimore) 2021;100:e26595. [PMID: 34232209 DOI: 10.1097/MD.0000000000026595] [Reference Citation Analysis]
116 Wadström J, Ericzon BG, Halloran PF, Bechstein WO, Opelz G, Serón D, Grinyó J, Loupy A, Kuypers D, Mariat C, Clancy M, Jardine AG, Guirado L, Fellström B, O'Grady J, Pirenne J, O'Leary JG, Aluvihare V, Trunečka P, Baccarani U, Neuberger J, Soto-Gutierrez A, Geissler EK, Metzger M, Gray M. Advancing Transplantation: New Questions, New Possibilities in Kidney and Liver Transplantation. Transplantation 2017;101 Suppl 2S:S1-S41. [PMID: 28125449 DOI: 10.1097/TP.0000000000001563] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 3.8] [Reference Citation Analysis]
117 Budde K, Bunnapradist S, Grinyo JM, Ciechanowski K, Denny JE, Silva HT, Rostaing L; on behalf of the Envarsus study group. Novel Once‐Daily Extended‐Release Tacrolimus (LCPT) Versus Twice‐Daily Tacrolimus in De Novo Kidney Transplants: One‐Year Results of Phase III, Double‐Blind, Randomized Trial. American Journal of Transplantation 2014;14:2796-806. [DOI: 10.1111/ajt.12955] [Cited by in Crossref: 56] [Cited by in F6Publishing: 43] [Article Influence: 7.0] [Reference Citation Analysis]
118 Süsal C, Döhler B. Late intra‐patient tacrolimus trough level variability as a major problem in kidney transplantation: A Collaborative Transplant Study Report. Am J Transplant 2019;19:2805-13. [DOI: 10.1111/ajt.15346] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
119 Sessa A, Esposito A, Iavicoli G, Lettieri E, Ragosta G, Rossano R, Capuano M. Cardiovascular Risk Factors in Renal Transplant Patients after Switch From Standard Tacrolimus to Prolonged-Release Tacrolimus. Transplantation Proceedings 2012;44:1901-6. [DOI: 10.1016/j.transproceed.2012.05.060] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
120 O'Regan JA, Canney M, Connaughton DM, O'Kelly P, Williams Y, Collier G, deFreitas DG, O'Seaghdha CM, Conlon PJ. Tacrolimus trough-level variability predicts long-term allograft survival following kidney transplantation. J Nephrol 2016;29:269-76. [PMID: 26374111 DOI: 10.1007/s40620-015-0230-0] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 5.1] [Reference Citation Analysis]
121 Choi HJ, Kim DG, Kwak BJ, Han JH, Hong TH, You YK. Comparison of the long-term efficacy and safety of generic tacrolimus, Tacrobell, with Prograf in liver transplant recipients. Drug Des Devel Ther 2018;12:295-301. [PMID: 29483770 DOI: 10.2147/DDDT.S149906] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
122 Budde K, Matz M. Tacrolimus only for breakfast …*: Invited commentary. Transplant International 2012;25:274-5. [DOI: 10.1111/j.1432-2277.2011.01422.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
123 Aktürk S, Erdoğmuş Ş, Kumru G, Elhan AH, Şengül Ş, Tüzüner A, Keven K. Average Tacrolimus Trough Level in the First Month After Transplantation May Predict Acute Rejection. Transplant Proc 2017;49:430-5. [PMID: 28340806 DOI: 10.1016/j.transproceed.2017.02.011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
124 González-vílchez F, Crespo-leiro MG, Delgado-jiménez J, Pérez-villa F, Segovia-cubero J, Díaz-molina B, Mirabet-pérez S, Arizón del Prado JM, Blasco-peiró T, Martínez-sellés M, Almenar-bonet L, Garrido-bravo I, Rábago G, Vázquez de Prada JA. Impacto de la variabilidad intrapaciente en la concentración sanguínea de anticalcineurínicos en los resultados del trasplante cardiaco. Revista Española de Cardiología 2022;75:129-40. [DOI: 10.1016/j.recesp.2021.02.004] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
125 Tanzi MG, Undre N, Keirns J, Fitzsimmons WE, Brown M, First MR. Pharmacokinetics of prolonged-release tacrolimus and implications for use in solid organ transplant recipients. Clin Transplant 2016;30:901-11. [PMID: 27220013 DOI: 10.1111/ctr.12763] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
126 Wu M, Cheng C, Chen C, Wu W, Cheng C, Yu D, Chuang Y, Shu K. Lower Variability of Tacrolimus Trough Concentration After Conversion From Prograf to Advagraf in Stable Kidney Transplant Recipients. Transplantation 2011;92:648-52. [DOI: 10.1097/tp.0b013e3182292426] [Cited by in Crossref: 80] [Cited by in F6Publishing: 18] [Article Influence: 7.3] [Reference Citation Analysis]
127 Goodall DL, Willicombe M, McLean AG, Taube D. High Intrapatient Variability of Tacrolimus Levels and Outpatient Clinic Nonattendance Are Associated With Inferior Outcomes in Renal Transplant Patients. Transplant Direct 2017;3:e192. [PMID: 28795143 DOI: 10.1097/TXD.0000000000000710] [Cited by in Crossref: 32] [Cited by in F6Publishing: 12] [Article Influence: 6.4] [Reference Citation Analysis]
128 van Gelder T, Fischer L, Shihab F, Shipkova M. Optimizing everolimus exposure when combined with calcineurin inhibitors in solid organ transplantation. Transplantation Reviews 2017;31:151-7. [DOI: 10.1016/j.trre.2017.02.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
129 Min S, Papaz T, Lafreniere-Roula M, Nalli N, Grasemann H, Schwartz SM, Kamath BM, Ng V, Parekh RS, Manlhiot C, Mital S. A randomized clinical trial of age and genotype-guided tacrolimus dosing after pediatric solid organ transplantation. Pediatr Transplant 2018;22:e13285. [PMID: 30178515 DOI: 10.1111/petr.13285] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
130 Unagami K, Ishida H, Furusawa M, Kitajima K, Hirai T, Kakuta Y, Toki D, Shimizu T, Omoto K, Okumi M, Nitta K, Tanabe K. Influence of a low-dose tacrolimus protocol on the appearance of de novo donor-specific antibodies during 7 years of follow-up after renal transplantation. Nephrol Dial Transplant 2021;36:1120-9. [PMID: 33280052 DOI: 10.1093/ndt/gfaa258] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
131 DuBay DA, Su Z, Morinelli TA, Baliga P, Rohan V, Bian J, Northrup D, Pilch N, Rao V, Srinivas TR, Mauldin PD, Taber DJ. Development and future deployment of a 5 years allograft survival model for kidney transplantation. Nephrology (Carlton) 2019;24:855-62. [PMID: 30198104 DOI: 10.1111/nep.13488] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
132 Piotti G, Cremaschi E, Maggiore U. Once-daily prolonged-release tacrolimus formulations for kidney transplantation: what the nephrologist needs to know. J Nephrol 2017;30:53-61. [DOI: 10.1007/s40620-016-0316-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
133 Lemaitre F, Tron C, Rayar M. Fluctuation Does Not Mean Variability: A Pharmacokinetic Point of View. Am J Transplant 2017;17:1691-2. [DOI: 10.1111/ajt.14237] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
134 Hauch A, John M, Smith A, Dortonne I, Patel U, Kandil E, Killackey M, Paramesh A, Lee B, Zhang R, Buell JF. Generics: Are all immunosuppression agents created equally? Surgery 2015;158:1049-55. [DOI: 10.1016/j.surg.2015.05.024] [Cited by in Crossref: 8] [Article Influence: 1.1] [Reference Citation Analysis]
135 Largeau B, Guellec CB, Longuet H, Lesne P, Bouvarel A, Préteseille L, Marquet P, Halimi JM, Büchler M, Gatault P, Noble J. Comparison of Tacrolimus Starting Doses Based on CYP3A5 Phenotype or Genotype in Kidney Transplant Recipients. Prog Transplant 2019;29:300-8. [PMID: 31514576 DOI: 10.1177/1526924819873905] [Reference Citation Analysis]
136 Giza P, Ficek R, Dwulit T, Chudek J, Woźniak I, Więcek A, Kolonko A. Number of Regularly Prescribed Drugs and Intrapatient Tacrolimus Trough Levels Variability in Stable Kidney Transplant Recipients. J Clin Med 2020;9:E1926. [PMID: 32575525 DOI: 10.3390/jcm9061926] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
137 Neuberger JM, Bechstein WO, Kuypers DR, Burra P, Citterio F, De Geest S, Duvoux C, Jardine AG, Kamar N, Krämer BK, Metselaar HJ, Nevens F, Pirenne J, Rodríguez-Perálvarez ML, Samuel D, Schneeberger S, Serón D, Trunečka P, Tisone G, van Gelder T. Practical Recommendations for Long-term Management of Modifiable Risks in Kidney and Liver Transplant Recipients: A Guidance Report and Clinical Checklist by the Consensus on Managing Modifiable Risk in Transplantation (COMMIT) Group. Transplantation 2017;101:S1-S56. [PMID: 28328734 DOI: 10.1097/TP.0000000000001651] [Cited by in Crossref: 114] [Cited by in F6Publishing: 43] [Article Influence: 22.8] [Reference Citation Analysis]
138 Størset E, Åsberg A, Skauby M, Neely M, Bergan S, Bremer S, Midtvedt K. Improved Tacrolimus Target Concentration Achievement Using Computerized Dosing in Renal Transplant Recipients--A Prospective, Randomized Study. Transplantation 2015;99:2158-66. [PMID: 25886918 DOI: 10.1097/TP.0000000000000708] [Cited by in Crossref: 54] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
139 Leino AD, King EC, Jiang W, Vinks AA, Klawitter J, Christians U, Woodle ES, Alloway RR, Rohan JM. Assessment of tacrolimus intrapatient variability in stable adherent transplant recipients: Establishing baseline values. Am J Transplant 2019;19:1410-20. [DOI: 10.1111/ajt.15199] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 9.3] [Reference Citation Analysis]
140 Alloway RR, Sadaka B, Trofe-Clark J, Wiland A, Bloom RD. A randomized pharmacokinetic study of generic tacrolimus versus reference tacrolimus in kidney transplant recipients. Am J Transplant 2012;12:2825-31. [PMID: 22759200 DOI: 10.1111/j.1600-6143.2012.04174.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 4.7] [Reference Citation Analysis]
141 Undre N, Dickinson J. Relative bioavailability of single doses of prolonged-release tacrolimus administered as a suspension, orally or via a nasogastric tube, compared with intact capsules: a phase 1 study in healthy participants. BMJ Open 2017;7:e012252. [PMID: 28377389 DOI: 10.1136/bmjopen-2016-012252] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
142 van Gelder T. Within-patient variability in immunosuppressive drug exposure as a predictor for poor outcome after transplantation. Kidney Int 2014;85:1267-8. [PMID: 24875549 DOI: 10.1038/ki.2013.484] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 4.9] [Reference Citation Analysis]
143 Andrews LM, Li Y, De Winter BCM, Shi YY, Baan CC, Van Gelder T, Hesselink DA. Pharmacokinetic considerations related to therapeutic drug monitoring of tacrolimus in kidney transplant patients. Expert Opin Drug Metab Toxicol 2017;13:1225-36. [PMID: 29084469 DOI: 10.1080/17425255.2017.1395413] [Cited by in Crossref: 59] [Cited by in F6Publishing: 45] [Article Influence: 11.8] [Reference Citation Analysis]
144 Prom A, Ricciuti D, Walter K, Newman J, Doligalski C. Impact of a clinical pharmacist in an outpatient heart transplant clinic. J Am Coll Clin Pharm 2021;4:1511-5. [DOI: 10.1002/jac5.1534] [Reference Citation Analysis]
145 Kim EJ, Kim SJ, Huh KH, Kim BS, Kim MS, Kim SI, Kim YS, Lee J. Clinical significance of tacrolimus intra-patient variability on kidney transplant outcomes according to pre-transplant immunological risk. Sci Rep 2021;11:12114. [PMID: 34108576 DOI: 10.1038/s41598-021-91630-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
146 Arreola-Guerra JM, Alberú J, Chew-Wong A, Macias DM, Hernández-Rosales J, Zuñiga-Macías L, Delgadillo-Castañeda R, Ricalde-Ríos G, Haro-Alcalde F, Villafán-Bernal JR, Ramos-Medellín CL, Reyes-Acevedo R. Changes in the commercial brand of tacrolimus lead to subtherapeutic trough levels and acute rejection in renal transplant recipients. Clin Transplant 2019;33:e13749. [PMID: 31691354 DOI: 10.1111/ctr.13749] [Reference Citation Analysis]
147 Allard J, Fortin MC. Is it ethical to prescribe generic immunosuppressive drugs to renal transplant patients? Can J Kidney Health Dis 2014;1:23. [PMID: 25780612 DOI: 10.1186/s40697-014-0023-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
148 Shuker N, Shuker L, van Rosmalen J, Roodnat JI, Borra LC, Weimar W, Hesselink DA, van Gelder T. A high intrapatient variability in tacrolimus exposure is associated with poor long-term outcome of kidney transplantation. Transpl Int 2016;29:1158-67. [PMID: 27188932 DOI: 10.1111/tri.12798] [Cited by in Crossref: 67] [Cited by in F6Publishing: 58] [Article Influence: 11.2] [Reference Citation Analysis]
149 Larpparisuth N, Pongnatcha T, Panprom P, Promraj R, Premasathian N, Vongwiwatana A. High Intrapatient Variability in Tacrolimus Exposure Calculated Over a Long Period Is Associated With De Novo Donor-Specific Antibody Development and/or Late Rejection in Thai Kidney Transplant Patients Receiving Concomitant CYP3A4/5 Inhibitors. Ther Drug Monit 2021;43:624-9. [PMID: 33278239 DOI: 10.1097/FTD.0000000000000850] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
150 Min SI, Ha J, Kang HG, Ahn S, Park T, Park DD, Kim SM, Hong HJ, Min SK, Ha IS, Kim SJ. Conversion of twice-daily tacrolimus to once-daily tacrolimus formulation in stable pediatric kidney transplant recipients: pharmacokinetics and efficacy. Am J Transplant 2013;13:2191-7. [PMID: 23734831 DOI: 10.1111/ajt.12274] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
151 Haasova M, Snowsill T, Jones-Hughes T, Crathorne L, Cooper C, Varley-Campbell J, Mujica-Mota R, Coelho H, Huxley N, Lowe J, Dudley J, Marks S, Hyde C, Bond M, Anderson R. Immunosuppressive therapy for kidney transplantation in children and adolescents: systematic review and economic evaluation. Health Technol Assess 2016;20:1-324. [PMID: 27557331 DOI: 10.3310/hta20610] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
152 Chu MC, Smith PJ, Reynolds JM, Palmer SM, Snyder LD, Gray AL, Blumenthal JA. Depression, Immunosuppressant Levels, and Clinical Outcomes in Postlung Transplant Recipients. Int J Psychiatry Med 2020;55:421-36. [DOI: 10.1177/0091217420906637] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
153 Shen CL, Wu BS, Lien TJ, Yang AH, Yang CY. BK Polyomavirus Nephropathy in Kidney Transplantation: Balancing Rejection and Infection. Viruses 2021;13:487. [PMID: 33809472 DOI: 10.3390/v13030487] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
154 Stefanović N, Veličković-Radovanović R, Danković K, Pavlović I, Catić-Đorđević A, Bašić J, Despotović M, Jevtović-Stoimenov T, Mitić B, Cvetković T. Effect of the Interrelation between CYP3A5 Genotype, Concentration/Dose Ratio and Intrapatient Variability of Tacrolimus on Kidney Graft Function: Monte Carlo Simulation Approach. Pharmaceutics 2021;13:1970. [PMID: 34834385 DOI: 10.3390/pharmaceutics13111970] [Reference Citation Analysis]
155 Mendoza Rojas A, Hesselink DA, van Besouw NM, Baan CC, van Gelder T. Impact of low tacrolimus exposure and high tacrolimus intra-patient variability on the development of de novo anti-HLA donor-specific antibodies in kidney transplant recipients. Expert Rev Clin Immunol 2019;15:1323-31. [PMID: 31721605 DOI: 10.1080/1744666X.2020.1693263] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
156 Hwang S, Song GW, Chung YK, Ahn CS, Kim KH, Moon DB, Ha TY, Jung DH, Park GC, Yoon YI, Cho HD, Kwon JH, Kang SH, Jeong IJ, Choi JU, Lee SG. Determination of Hepatitis B Immunoglobulin Infusion Interval Using Pharmacokinetic Half-life Simulation for Posttransplant Hepatitis B Prophylaxis. J Korean Med Sci 2019;34:e251. [PMID: 31583871 DOI: 10.3346/jkms.2019.34.e251] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
157 Sharma A, Cherukuri A, Mehta RB, Sood P, Hariharan S. High Calcineurin Inhibitor Intrapatient Variability Is Associated With Renal Allograft Inflammation, Chronicity, and Graft Loss. Transplant Direct 2019;5:e424. [PMID: 30882028 DOI: 10.1097/TXD.0000000000000862] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
158 Mo H, Kim SY, Min S, Han A, Ahn S, Min SK, Lee H, Ahn C, Kim Y, Ha J. Association of Intrapatient Variability of Tacrolimus Concentration With Early Deterioration of Chronic Histologic Lesions in Kidney Transplantation. Transplant Direct 2019;5:e455. [PMID: 31321291 DOI: 10.1097/TXD.0000000000000899] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
159 Taber DJ, Su Z, Fleming JN, McGillicuddy JW, Posadas-Salas MA, Treiber FA, Dubay D, Srinivas TR, Mauldin PD, Moran WP. Tacrolimus Trough Concentration Variability and Disparities in African American Kidney Transplantation. Transplantation. 2017;101:2931-2938. [PMID: 28658199 DOI: 10.1097/tp.0000000000001840] [Cited by in Crossref: 39] [Cited by in F6Publishing: 19] [Article Influence: 7.8] [Reference Citation Analysis]